NDAORALTABLET
Approved
Sep 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AQUATENSEN (methyclothiazide) is an oral thiazide diuretic approved in 1977 for hypertension and edema management. It reduces fluid volume and peripheral vascular resistance through inhibition of sodium reabsorption in the distal convoluted tubule. This agent is indicated for patients requiring antihypertensive or diuretic therapy.
LOE Approaching
This mature product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling transition from growth-focused teams to maintenance and generic defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers limited career growth potential due to its LOE-approaching lifecycle and zero linked job count. Working on AQUATENSEN is primarily suitable for professionals seeking stable, defensive brand management experience rather than high-growth commercial trajectories.
Brand ManagerField Sales Representative
Worked on AQUATENSEN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.